Amicogen Inc (092040) - Total Assets
Based on the latest financial reports, Amicogen Inc (092040) holds total assets worth ₩213.68 Billion KRW (≈ $144.81 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Amicogen Inc (092040) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Amicogen Inc - Total Assets Trend (2014–2025)
This chart illustrates how Amicogen Inc's total assets have evolved over time, based on quarterly financial data. See 092040 net asset value for net asset value and shareholders' equity analysis.
Amicogen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Amicogen Inc's total assets of ₩213.68 Billion consist of 16.3% current assets and 83.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.7% |
| Accounts Receivable | ₩8.60 Billion | 3.7% |
| Inventory | ₩12.94 Billion | 5.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩9.67 Billion | 4.2% |
| Goodwill | ₩1.71 Billion | 0.7% |
Asset Composition Trend (2014–2025)
This chart illustrates how Amicogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Amicogen Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amicogen Inc's current assets represent 16.3% of total assets in 2025, a decrease from 56.0% in 2014.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, down from 15.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 5.6% of total assets.
Amicogen Inc Competitors by Total Assets
Key competitors of Amicogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Amicogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 0.79 | 1.33 |
| Quick Ratio | 0.84 | 0.67 | 1.06 |
| Cash Ratio | 0.00 | 0.18 | 0.21 |
| Working Capital | ₩2.88 Billion | ₩-18.34 Billion | ₩45.42 Billion |
Amicogen Inc - Advanced Valuation Insights
This section examines the relationship between Amicogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | ₩231.86 Billion |
| Market Capitalization | $42.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Amicogen Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Amicogen Inc's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Amicogen Inc (2014–2025)
The table below shows the annual total assets of Amicogen Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩231.86 Billion ≈ $157.13 Million |
-21.20% |
| 2024-12-31 | ₩294.23 Billion ≈ $199.39 Million |
-37.01% |
| 2023-12-31 | ₩467.10 Billion ≈ $316.55 Million |
+8.72% |
| 2022-12-31 | ₩429.65 Billion ≈ $291.17 Million |
+4.48% |
| 2021-12-31 | ₩411.22 Billion ≈ $278.68 Million |
+45.12% |
| 2020-12-31 | ₩283.37 Billion ≈ $192.03 Million |
+17.38% |
| 2019-12-31 | ₩241.40 Billion ≈ $163.59 Million |
+4.41% |
| 2018-12-31 | ₩231.21 Billion ≈ $156.69 Million |
+41.40% |
| 2017-12-31 | ₩163.51 Billion ≈ $110.81 Million |
+11.74% |
| 2016-12-31 | ₩146.33 Billion ≈ $99.17 Million |
-8.45% |
| 2015-12-31 | ₩159.84 Billion ≈ $108.32 Million |
+194.01% |
| 2014-12-31 | ₩54.37 Billion ≈ $36.84 Million |
-- |
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more